# TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma

> **NCT04103398** · PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 162 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Sorafenib
- Transarterial Chemoembolization

## Interventions

- **COMBINATION_PRODUCT:** TACE+sorafenib
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT04103398
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-02
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04103398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04103398, "TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04103398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*